nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP1A2—Carmustine—lymphatic system cancer	0.103	0.147	CbGbCtD
Haloperidol—CYP3A5—Teniposide—lymphatic system cancer	0.0933	0.132	CbGbCtD
Haloperidol—CYP2C19—Teniposide—lymphatic system cancer	0.0753	0.107	CbGbCtD
Haloperidol—CYP2C9—Teniposide—lymphatic system cancer	0.0626	0.0888	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0599	0.0849	CbGbCtD
Haloperidol—CYP3A7—Vincristine—lymphatic system cancer	0.0599	0.0849	CbGbCtD
Haloperidol—CYP3A5—Vincristine—lymphatic system cancer	0.0449	0.0637	CbGbCtD
Haloperidol—ABCB1—Mitoxantrone—lymphatic system cancer	0.0425	0.0603	CbGbCtD
Haloperidol—CYP3A4—Cytarabine—lymphatic system cancer	0.0369	0.0524	CbGbCtD
Haloperidol—CYP3A4—Teniposide—lymphatic system cancer	0.0364	0.0516	CbGbCtD
Haloperidol—ABCB1—Vincristine—lymphatic system cancer	0.0292	0.0415	CbGbCtD
Haloperidol—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0254	0.0361	CbGbCtD
Haloperidol—ABCB1—Methotrexate—lymphatic system cancer	0.0177	0.0251	CbGbCtD
Haloperidol—CYP3A4—Vincristine—lymphatic system cancer	0.0175	0.0248	CbGbCtD
Haloperidol—CBR1—Azacitidine—Fludarabine—lymphatic system cancer	0.00245	0.306	CbGdCrCtD
Haloperidol—CBR1—Azacitidine—Cytarabine—lymphatic system cancer	0.00232	0.289	CbGdCrCtD
Haloperidol—EBP—Azacitidine—Fludarabine—lymphatic system cancer	0.00167	0.208	CbGdCrCtD
Haloperidol—EBP—Azacitidine—Cytarabine—lymphatic system cancer	0.00158	0.197	CbGdCrCtD
Haloperidol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00106	0.00369	CcSEcCtD
Haloperidol—Leukopenia—Fludarabine—lymphatic system cancer	0.00106	0.00367	CcSEcCtD
Haloperidol—Pruritus—Mechlorethamine—lymphatic system cancer	0.00105	0.00366	CcSEcCtD
Haloperidol—Anorexia—Teniposide—lymphatic system cancer	0.00104	0.00363	CcSEcCtD
Haloperidol—Pancytopenia—Carmustine—lymphatic system cancer	0.00103	0.00358	CcSEcCtD
Haloperidol—Hypotension—Teniposide—lymphatic system cancer	0.00102	0.00356	CcSEcCtD
Haloperidol—Convulsion—Fludarabine—lymphatic system cancer	0.00102	0.00356	CcSEcCtD
Haloperidol—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00102	0.00354	CcSEcCtD
Haloperidol—Neutropenia—Carmustine—lymphatic system cancer	0.00101	0.00353	CcSEcCtD
Haloperidol—Pancytopenia—Vincristine—lymphatic system cancer	0.000982	0.00342	CcSEcCtD
Haloperidol—Sweating increased—Mitoxantrone—lymphatic system cancer	0.000981	0.00341	CcSEcCtD
Haloperidol—Hyperglycaemia—Carmustine—lymphatic system cancer	0.000977	0.0034	CcSEcCtD
Haloperidol—Dyspnoea—Teniposide—lymphatic system cancer	0.000976	0.0034	CcSEcCtD
Haloperidol—Confusional state—Fludarabine—lymphatic system cancer	0.00097	0.00338	CcSEcCtD
Haloperidol—Neutropenia—Vincristine—lymphatic system cancer	0.000967	0.00337	CcSEcCtD
Haloperidol—Depression—Carmustine—lymphatic system cancer	0.000963	0.00335	CcSEcCtD
Haloperidol—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000962	0.00335	CcSEcCtD
Haloperidol—Oedema—Fludarabine—lymphatic system cancer	0.000962	0.00335	CcSEcCtD
Haloperidol—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000956	0.00333	CcSEcCtD
Haloperidol—Erectile dysfunction—Vincristine—lymphatic system cancer	0.000952	0.00332	CcSEcCtD
Haloperidol—Decreased appetite—Teniposide—lymphatic system cancer	0.000952	0.00331	CcSEcCtD
Haloperidol—Vomiting—Mechlorethamine—lymphatic system cancer	0.000944	0.00329	CcSEcCtD
Haloperidol—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000944	0.00329	CcSEcCtD
Haloperidol—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.000944	0.00329	CcSEcCtD
Haloperidol—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000942	0.00328	CcSEcCtD
Haloperidol—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000942	0.00328	CcSEcCtD
Haloperidol—Rash—Mechlorethamine—lymphatic system cancer	0.000936	0.00326	CcSEcCtD
Haloperidol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000936	0.00326	CcSEcCtD
Haloperidol—Weight decreased—Vincristine—lymphatic system cancer	0.000935	0.00326	CcSEcCtD
Haloperidol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00093	0.00324	CcSEcCtD
Haloperidol—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000927	0.00323	CcSEcCtD
Haloperidol—Depression—Vincristine—lymphatic system cancer	0.000919	0.0032	CcSEcCtD
Haloperidol—Anorexia—Fludarabine—lymphatic system cancer	0.000917	0.00319	CcSEcCtD
Haloperidol—Weight increased—Mitoxantrone—lymphatic system cancer	0.000916	0.00319	CcSEcCtD
Haloperidol—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000911	0.00317	CcSEcCtD
Haloperidol—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.000908	0.00316	CcSEcCtD
Haloperidol—Feeling abnormal—Teniposide—lymphatic system cancer	0.000902	0.00314	CcSEcCtD
Haloperidol—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000898	0.00313	CcSEcCtD
Haloperidol—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.000891	0.0031	CcSEcCtD
Haloperidol—Nausea—Mechlorethamine—lymphatic system cancer	0.000882	0.00307	CcSEcCtD
Haloperidol—Alopecia—Bleomycin—lymphatic system cancer	0.000878	0.00306	CcSEcCtD
Haloperidol—Jaundice—Mitoxantrone—lymphatic system cancer	0.000875	0.00305	CcSEcCtD
Haloperidol—Urticaria—Teniposide—lymphatic system cancer	0.00087	0.00303	CcSEcCtD
Haloperidol—Body temperature increased—Teniposide—lymphatic system cancer	0.000866	0.00301	CcSEcCtD
Haloperidol—Hallucination—Carmustine—lymphatic system cancer	0.000863	0.003	CcSEcCtD
Haloperidol—Dyspnoea—Fludarabine—lymphatic system cancer	0.000858	0.00299	CcSEcCtD
Haloperidol—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000852	0.00297	CcSEcCtD
Haloperidol—Dyspepsia—Fludarabine—lymphatic system cancer	0.000847	0.00295	CcSEcCtD
Haloperidol—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000838	0.00292	CcSEcCtD
Haloperidol—Decreased appetite—Fludarabine—lymphatic system cancer	0.000837	0.00291	CcSEcCtD
Haloperidol—Visual impairment—Carmustine—lymphatic system cancer	0.000835	0.00291	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000831	0.00289	CcSEcCtD
Haloperidol—Hallucination—Vincristine—lymphatic system cancer	0.000823	0.00287	CcSEcCtD
Haloperidol—Constipation—Fludarabine—lymphatic system cancer	0.000823	0.00287	CcSEcCtD
Haloperidol—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000817	0.00285	CcSEcCtD
Haloperidol—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000813	0.00283	CcSEcCtD
Haloperidol—Urethral disorder—Vincristine—lymphatic system cancer	0.000811	0.00282	CcSEcCtD
Haloperidol—Eye disorder—Carmustine—lymphatic system cancer	0.00081	0.00282	CcSEcCtD
Haloperidol—Hypersensitivity—Teniposide—lymphatic system cancer	0.000807	0.00281	CcSEcCtD
Haloperidol—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000806	0.00281	CcSEcCtD
Haloperidol—Anaemia—Bleomycin—lymphatic system cancer	0.000799	0.00278	CcSEcCtD
Haloperidol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000793	0.00276	CcSEcCtD
Haloperidol—Pruritus—Teniposide—lymphatic system cancer	0.000775	0.0027	CcSEcCtD
Haloperidol—Leukopenia—Bleomycin—lymphatic system cancer	0.000774	0.00269	CcSEcCtD
Haloperidol—Cardiac disorder—Vincristine—lymphatic system cancer	0.000768	0.00267	CcSEcCtD
Haloperidol—Alopecia—Carmustine—lymphatic system cancer	0.000766	0.00267	CcSEcCtD
Haloperidol—Body temperature increased—Fludarabine—lymphatic system cancer	0.000761	0.00265	CcSEcCtD
Haloperidol—Mental disorder—Carmustine—lymphatic system cancer	0.00076	0.00264	CcSEcCtD
Haloperidol—Malnutrition—Carmustine—lymphatic system cancer	0.000755	0.00263	CcSEcCtD
Haloperidol—Angiopathy—Vincristine—lymphatic system cancer	0.000751	0.00261	CcSEcCtD
Haloperidol—Diarrhoea—Teniposide—lymphatic system cancer	0.000749	0.00261	CcSEcCtD
Haloperidol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000746	0.0026	CcSEcCtD
Haloperidol—Alopecia—Vincristine—lymphatic system cancer	0.000731	0.00255	CcSEcCtD
Haloperidol—Mental disorder—Vincristine—lymphatic system cancer	0.000725	0.00252	CcSEcCtD
Haloperidol—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000715	0.00249	CcSEcCtD
Haloperidol—Alopecia—Mitoxantrone—lymphatic system cancer	0.000712	0.00248	CcSEcCtD
Haloperidol—Confusional state—Bleomycin—lymphatic system cancer	0.000711	0.00248	CcSEcCtD
Haloperidol—Vision blurred—Carmustine—lymphatic system cancer	0.000711	0.00248	CcSEcCtD
Haloperidol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000709	0.00247	CcSEcCtD
Haloperidol—Tremor—Carmustine—lymphatic system cancer	0.000707	0.00246	CcSEcCtD
Haloperidol—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000706	0.00246	CcSEcCtD
Haloperidol—Oedema—Bleomycin—lymphatic system cancer	0.000706	0.00246	CcSEcCtD
Haloperidol—Anaemia—Carmustine—lymphatic system cancer	0.000698	0.00243	CcSEcCtD
Haloperidol—Vomiting—Teniposide—lymphatic system cancer	0.000696	0.00242	CcSEcCtD
Haloperidol—Agitation—Carmustine—lymphatic system cancer	0.000694	0.00241	CcSEcCtD
Haloperidol—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000691	0.00241	CcSEcCtD
Haloperidol—Rash—Teniposide—lymphatic system cancer	0.00069	0.0024	CcSEcCtD
Haloperidol—Dermatitis—Teniposide—lymphatic system cancer	0.00069	0.0024	CcSEcCtD
Haloperidol—Headache—Teniposide—lymphatic system cancer	0.000686	0.00239	CcSEcCtD
Haloperidol—Pruritus—Fludarabine—lymphatic system cancer	0.000681	0.00237	CcSEcCtD
Haloperidol—Leukopenia—Carmustine—lymphatic system cancer	0.000676	0.00235	CcSEcCtD
Haloperidol—Anorexia—Bleomycin—lymphatic system cancer	0.000673	0.00234	CcSEcCtD
Haloperidol—Anaemia—Vincristine—lymphatic system cancer	0.000666	0.00232	CcSEcCtD
Haloperidol—Agitation—Vincristine—lymphatic system cancer	0.000662	0.0023	CcSEcCtD
Haloperidol—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000661	0.0023	CcSEcCtD
Haloperidol—Photosensitivity—Methotrexate—lymphatic system cancer	0.000661	0.0023	CcSEcCtD
Haloperidol—Hypotension—Bleomycin—lymphatic system cancer	0.000659	0.0023	CcSEcCtD
Haloperidol—Diarrhoea—Fludarabine—lymphatic system cancer	0.000658	0.00229	CcSEcCtD
Haloperidol—Convulsion—Carmustine—lymphatic system cancer	0.000654	0.00228	CcSEcCtD
Haloperidol—Hypertension—Carmustine—lymphatic system cancer	0.000652	0.00227	CcSEcCtD
Haloperidol—Nausea—Teniposide—lymphatic system cancer	0.00065	0.00226	CcSEcCtD
Haloperidol—Anaemia—Mitoxantrone—lymphatic system cancer	0.000648	0.00226	CcSEcCtD
Haloperidol—Vertigo—Vincristine—lymphatic system cancer	0.000647	0.00225	CcSEcCtD
Haloperidol—Leukopenia—Vincristine—lymphatic system cancer	0.000645	0.00225	CcSEcCtD
Haloperidol—Anxiety—Carmustine—lymphatic system cancer	0.00064	0.00223	CcSEcCtD
Haloperidol—Dyspnoea—Bleomycin—lymphatic system cancer	0.000629	0.00219	CcSEcCtD
Haloperidol—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000628	0.00219	CcSEcCtD
Haloperidol—Convulsion—Vincristine—lymphatic system cancer	0.000624	0.00217	CcSEcCtD
Haloperidol—Hypertension—Vincristine—lymphatic system cancer	0.000622	0.00217	CcSEcCtD
Haloperidol—Confusional state—Carmustine—lymphatic system cancer	0.000621	0.00216	CcSEcCtD
Haloperidol—Oedema—Carmustine—lymphatic system cancer	0.000616	0.00214	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000615	0.00214	CcSEcCtD
Haloperidol—Decreased appetite—Bleomycin—lymphatic system cancer	0.000613	0.00214	CcSEcCtD
Haloperidol—Visual disturbance—Methotrexate—lymphatic system cancer	0.000613	0.00213	CcSEcCtD
Haloperidol—Vomiting—Fludarabine—lymphatic system cancer	0.000612	0.00213	CcSEcCtD
Haloperidol—Convulsion—Mitoxantrone—lymphatic system cancer	0.000608	0.00212	CcSEcCtD
Haloperidol—Rash—Fludarabine—lymphatic system cancer	0.000607	0.00211	CcSEcCtD
Haloperidol—Dermatitis—Fludarabine—lymphatic system cancer	0.000606	0.00211	CcSEcCtD
Haloperidol—Hypertension—Mitoxantrone—lymphatic system cancer	0.000606	0.00211	CcSEcCtD
Haloperidol—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000603	0.0021	CcSEcCtD
Haloperidol—Headache—Fludarabine—lymphatic system cancer	0.000603	0.0021	CcSEcCtD
Haloperidol—Tachycardia—Carmustine—lymphatic system cancer	0.000601	0.00209	CcSEcCtD
Haloperidol—Anxiety—Mitoxantrone—lymphatic system cancer	0.000595	0.00207	CcSEcCtD
Haloperidol—Lethargy—Methotrexate—lymphatic system cancer	0.000592	0.00206	CcSEcCtD
Haloperidol—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000588	0.00205	CcSEcCtD
Haloperidol—Oedema—Vincristine—lymphatic system cancer	0.000588	0.00205	CcSEcCtD
Haloperidol—Anorexia—Carmustine—lymphatic system cancer	0.000587	0.00204	CcSEcCtD
Haloperidol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000581	0.00202	CcSEcCtD
Haloperidol—Confusional state—Mitoxantrone—lymphatic system cancer	0.000577	0.00201	CcSEcCtD
Haloperidol—Nervous system disorder—Vincristine—lymphatic system cancer	0.000577	0.00201	CcSEcCtD
Haloperidol—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000576	0.002	CcSEcCtD
Haloperidol—Hypotension—Carmustine—lymphatic system cancer	0.000576	0.002	CcSEcCtD
Haloperidol—Oedema—Mitoxantrone—lymphatic system cancer	0.000573	0.00199	CcSEcCtD
Haloperidol—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000573	0.00199	CcSEcCtD
Haloperidol—Nausea—Fludarabine—lymphatic system cancer	0.000572	0.00199	CcSEcCtD
Haloperidol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000568	0.00198	CcSEcCtD
Haloperidol—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000561	0.00195	CcSEcCtD
Haloperidol—Urticaria—Bleomycin—lymphatic system cancer	0.000561	0.00195	CcSEcCtD
Haloperidol—Anorexia—Vincristine—lymphatic system cancer	0.00056	0.00195	CcSEcCtD
Haloperidol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000559	0.00195	CcSEcCtD
Haloperidol—Body temperature increased—Bleomycin—lymphatic system cancer	0.000558	0.00194	CcSEcCtD
Haloperidol—Insomnia—Carmustine—lymphatic system cancer	0.000557	0.00194	CcSEcCtD
Haloperidol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000556	0.00194	CcSEcCtD
Haloperidol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000554	0.00193	CcSEcCtD
Haloperidol—Hypotension—Vincristine—lymphatic system cancer	0.000549	0.00191	CcSEcCtD
Haloperidol—Dyspnoea—Carmustine—lymphatic system cancer	0.000549	0.00191	CcSEcCtD
Haloperidol—Somnolence—Carmustine—lymphatic system cancer	0.000548	0.00191	CcSEcCtD
Haloperidol—Anorexia—Mitoxantrone—lymphatic system cancer	0.000546	0.0019	CcSEcCtD
Haloperidol—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000536	0.00187	CcSEcCtD
Haloperidol—Decreased appetite—Carmustine—lymphatic system cancer	0.000535	0.00186	CcSEcCtD
Haloperidol—Hypotension—Mitoxantrone—lymphatic system cancer	0.000535	0.00186	CcSEcCtD
Haloperidol—Insomnia—Vincristine—lymphatic system cancer	0.000532	0.00185	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000532	0.00185	CcSEcCtD
Haloperidol—Constipation—Carmustine—lymphatic system cancer	0.000527	0.00183	CcSEcCtD
Haloperidol—Breast disorder—Methotrexate—lymphatic system cancer	0.000525	0.00183	CcSEcCtD
Haloperidol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00052	0.00181	CcSEcCtD
Haloperidol—Decreased appetite—Vincristine—lymphatic system cancer	0.000511	0.00178	CcSEcCtD
Haloperidol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00051	0.00178	CcSEcCtD
Haloperidol—Somnolence—Mitoxantrone—lymphatic system cancer	0.000509	0.00177	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000508	0.00177	CcSEcCtD
Haloperidol—Feeling abnormal—Carmustine—lymphatic system cancer	0.000508	0.00177	CcSEcCtD
Haloperidol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000504	0.00175	CcSEcCtD
Haloperidol—Constipation—Vincristine—lymphatic system cancer	0.000503	0.00175	CcSEcCtD
Haloperidol—Pruritus—Bleomycin—lymphatic system cancer	0.000499	0.00174	CcSEcCtD
Haloperidol—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000498	0.00173	CcSEcCtD
Haloperidol—Constipation—Mitoxantrone—lymphatic system cancer	0.00049	0.0017	CcSEcCtD
Haloperidol—Body temperature increased—Carmustine—lymphatic system cancer	0.000487	0.0017	CcSEcCtD
Haloperidol—Pancytopenia—Methotrexate—lymphatic system cancer	0.000476	0.00166	CcSEcCtD
Haloperidol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000472	0.00164	CcSEcCtD
Haloperidol—Neutropenia—Methotrexate—lymphatic system cancer	0.000469	0.00163	CcSEcCtD
Haloperidol—Body temperature increased—Vincristine—lymphatic system cancer	0.000465	0.00162	CcSEcCtD
Haloperidol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000462	0.00161	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000458	0.00159	CcSEcCtD
Haloperidol—Urticaria—Mitoxantrone—lymphatic system cancer	0.000455	0.00158	CcSEcCtD
Haloperidol—Hypersensitivity—Carmustine—lymphatic system cancer	0.000454	0.00158	CcSEcCtD
Haloperidol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000453	0.00158	CcSEcCtD
Haloperidol—Vomiting—Bleomycin—lymphatic system cancer	0.000449	0.00156	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—lymphatic system cancer	0.000447	0.00156	CcSEcCtD
Haloperidol—Depression—Methotrexate—lymphatic system cancer	0.000446	0.00155	CcSEcCtD
Haloperidol—Rash—Bleomycin—lymphatic system cancer	0.000445	0.00155	CcSEcCtD
Haloperidol—Dermatitis—Bleomycin—lymphatic system cancer	0.000444	0.00155	CcSEcCtD
Haloperidol—Hypersensitivity—Vincristine—lymphatic system cancer	0.000433	0.00151	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000423	0.00147	CcSEcCtD
Haloperidol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000422	0.00147	CcSEcCtD
Haloperidol—Diarrhoea—Carmustine—lymphatic system cancer	0.000421	0.00147	CcSEcCtD
Haloperidol—Nausea—Bleomycin—lymphatic system cancer	0.000419	0.00146	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000417	0.00145	CcSEcCtD
Haloperidol—Dizziness—Carmustine—lymphatic system cancer	0.000407	0.00142	CcSEcCtD
Haloperidol—Diarrhoea—Vincristine—lymphatic system cancer	0.000402	0.0014	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—lymphatic system cancer	0.000402	0.0014	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000397	0.00138	CcSEcCtD
Haloperidol—Urethral disorder—Methotrexate—lymphatic system cancer	0.000394	0.00137	CcSEcCtD
Haloperidol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000392	0.00136	CcSEcCtD
Haloperidol—Vomiting—Carmustine—lymphatic system cancer	0.000392	0.00136	CcSEcCtD
Haloperidol—Dizziness—Vincristine—lymphatic system cancer	0.000389	0.00135	CcSEcCtD
Haloperidol—Rash—Carmustine—lymphatic system cancer	0.000388	0.00135	CcSEcCtD
Haloperidol—Dermatitis—Carmustine—lymphatic system cancer	0.000388	0.00135	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—lymphatic system cancer	0.000387	0.00135	CcSEcCtD
Haloperidol—Headache—Carmustine—lymphatic system cancer	0.000386	0.00134	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—lymphatic system cancer	0.000375	0.00131	CcSEcCtD
Haloperidol—Vomiting—Vincristine—lymphatic system cancer	0.000374	0.0013	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000373	0.0013	CcSEcCtD
Haloperidol—Rash—Vincristine—lymphatic system cancer	0.000371	0.00129	CcSEcCtD
Haloperidol—Dermatitis—Vincristine—lymphatic system cancer	0.00037	0.00129	CcSEcCtD
Haloperidol—Headache—Vincristine—lymphatic system cancer	0.000368	0.00128	CcSEcCtD
Haloperidol—Nausea—Carmustine—lymphatic system cancer	0.000366	0.00127	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—lymphatic system cancer	0.000364	0.00127	CcSEcCtD
Haloperidol—Vomiting—Mitoxantrone—lymphatic system cancer	0.000364	0.00127	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—lymphatic system cancer	0.000363	0.00126	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000362	0.00126	CcSEcCtD
Haloperidol—Rash—Mitoxantrone—lymphatic system cancer	0.000361	0.00126	CcSEcCtD
Haloperidol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000361	0.00126	CcSEcCtD
Haloperidol—Headache—Mitoxantrone—lymphatic system cancer	0.000359	0.00125	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—lymphatic system cancer	0.000355	0.00124	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—lymphatic system cancer	0.000352	0.00122	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—lymphatic system cancer	0.00035	0.00122	CcSEcCtD
Haloperidol—Nausea—Vincristine—lymphatic system cancer	0.000349	0.00122	CcSEcCtD
Haloperidol—Nausea—Mitoxantrone—lymphatic system cancer	0.00034	0.00118	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—lymphatic system cancer	0.000329	0.00115	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—lymphatic system cancer	0.000323	0.00112	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—lymphatic system cancer	0.000314	0.00109	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—lymphatic system cancer	0.000313	0.00109	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—lymphatic system cancer	0.000303	0.00105	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000296	0.00103	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—lymphatic system cancer	0.000288	0.001	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000285	0.000993	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00028	0.000974	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000279	0.000972	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—lymphatic system cancer	0.000277	0.000965	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000276	0.00096	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—lymphatic system cancer	0.000272	0.000947	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—lymphatic system cancer	0.000267	0.000928	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—lymphatic system cancer	0.000258	0.000898	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000254	0.000886	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—lymphatic system cancer	0.000254	0.000883	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—lymphatic system cancer	0.000251	0.000874	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—lymphatic system cancer	0.000248	0.000863	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000246	0.000857	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000235	0.000818	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—lymphatic system cancer	0.000227	0.000789	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—lymphatic system cancer	0.000226	0.000785	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00021	0.000732	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—lymphatic system cancer	0.000202	0.000703	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—lymphatic system cancer	0.000195	0.00068	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—lymphatic system cancer	0.000189	0.000657	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—lymphatic system cancer	0.000181	0.000632	CcSEcCtD
Haloperidol—Rash—Methotrexate—lymphatic system cancer	0.00018	0.000626	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—lymphatic system cancer	0.00018	0.000626	CcSEcCtD
Haloperidol—Headache—Methotrexate—lymphatic system cancer	0.000179	0.000622	CcSEcCtD
Haloperidol—Nausea—Methotrexate—lymphatic system cancer	0.000169	0.00059	CcSEcCtD
